Blood test may predict immunotherapy success in advanced cancers

NCT ID NCT06227728

First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This study looks at whether changes in a blood marker called ctDNA can help doctors tell early on if immunotherapy is working for people with advanced cancers like lung, breast, colorectal, stomach, or liver cancer. Researchers will also check other markers like PD-L1 and TMB to see which best predicts treatment response. About 50 adults with stage IV cancer who are starting immunotherapy will participate. This is an observational study, meaning no new treatments are given—just extra blood tests and scans to monitor how the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medical Genetics Institute

    NOT_YET_RECRUITING

    Ho Chi Minh City, Vietnam

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Medicine and Pharmacy at HCMC

    RECRUITING

    Ho Chi Minh City, Hồ Chí Minh, Vietnam

    Contact

Conditions

Explore the condition pages connected to this study.